ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2176

Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease
Abstract Number: 1910

Appointment Adherence: Impact of Health Portal Access, Letters, Phone Calls and Text Message Reminders in Underserved Population
Abstract Number: 1265

Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Abstract Number: 2583

Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
Abstract Number: 1466

Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial
Abstract Number: 2229

Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination
Abstract Number: 2472

Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?
Abstract Number: 0178

Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?
Abstract Number: 1671

Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Abstract Number: 0771

Arid5b Controls Pathologic Inflammatory versus Invasive Fibroblast Behavior
Abstract Number: 0689

Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis
Abstract Number: 1612

Arterial Involvement Distribution on 18FFDG PET-CT in Giant Cell Arteritis: Variances Based on Clinical Phenotype
Abstract Number: 1633

Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
Abstract Number: 0034

Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis
Abstract Number: 1976

Artificial Intelligence Analysis of HRCT Images Reflects Pulmonary Involvement in Systemic Sclerosis Interstitial Lung Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].